Should You Cover GLP-1s in 2026? A Data-Driven Framework
43% of large employers now cover these drugs. Here’s how to make your decision
No benefits decision in 2026 is generating more debate than GLP-1 coverage. Ozempic, Wegovy, Mounjaro, Zepbound—these drugs have moved from diabetes treatment to weight loss phenomenon to the single biggest driver of pharmacy spend in less than three years.
Your employees are asking about them. Your broker is asking about them. Your CFO is asking about the cost. And there’s no industry consensus on the right answer.
This is a complex decision. Here’s how to think through it clearly.
Key Takeaways
43% of employers with 5,000+ employees now cover GLP-1s for weight loss (up from 28% in 2024)
Annual cost per patient: $9,200-$16,000 depending on drug and rebates
ROI timeline: Medical cost trend cuts in half by year 2, with 44% reduction in cardiac events
The catch: 50% discontinuation rate in year 1, and employee turnover may limit your ROI
85% of employers offering GLP-1s use utilization management to control costs
The Numbers That Matter
Metric | Value |
|---|---|
Large employers covering GLP-1s for weight loss | 43% |
Pharmacy spend going to just 5 GLP-1 drugs | 21% |
Potential premium increase from coverage | 14% |
The Cost Reality
Let’s start with the numbers that matter most to your finance team.
Per-Patient Annual Cost: $9,200 - $16,000
Net of rebates and discounts. Wegovy leads at $16,000+/year. Generic alternatives are still years away.
Impact on Total Pharmacy Spend: +2% to 15%
Average is 2-5% increase. High-utilization groups (older workforce, high obesity rates) can see 10-15%.
Per-Member-Per-Month (PMPM): $10 - $25
Additional pharmacy PMPM cost. For a 1,000-employee company, that’s $120,000-$300,000 annually.
The Pharmacy Spend Explosion
Year | GLP-1 PMPM Cost | % of Pharmacy Spend |
|---|---|---|
2019 | $1.43 | ~1% |
2021 | $4.82 | ~3% |
2023 | $12.40 | 6.9% |
2025 | $24.59 | 10.5%+ |
That’s a 77% compound annual growth rate in GLP-1 spending since 2019. Pharmacy costs have risen from 15% to 25% of total healthcare spend—and half of that increase comes from just five drugs, three of which are GLP-1s.
The Coverage Reality: What Your Peers Are Doing
Employer Size | Coverage Rate | Trend |
|---|---|---|
5,000+ employees | 43% | ↑ 15 points from 2024 |
200+ employees | 19% | Varies by industry |
Coverage by Condition
Coverage Type | % of Employers |
|---|---|
Diabetes only | 35% |
Obesity + Cardiovascular risk | 23% |
Comprehensive (all approved uses) | 29% |
No GLP-1 coverage | 12% |
The Rethink Is Underway
Despite rising adoption, 85% of employers offering GLP-1s are considering additional restrictions for 2026. And 15% are either removing coverage (6%) or considering it (9%). The honeymoon phase is over—employers are now focused on sustainable coverage models.
The ROI Question: Does It Pay Off?
This is the $16,000 question. Here’s what the research shows.
Year 1: Net Negative
Drug costs far exceed medical savings. Expect $6,500+ net cost per patient after accounting for ~$560 in reduced medical claims.
Year 2: Inflection Point
Medical cost trend cuts roughly in half. Aon research shows the growth rate of medical costs slows by 7% on average for GLP-1 users.
Year 2+: Cardiovascular Benefits Emerge
44% reduction in major cardiac events (heart attacks, strokes). Reduced diabetes onset. These are the big savings drivers.
The Case FOR Coverage
44% reduction in major cardiac events by year 2
Reduced onset of Type 2 diabetes
Improved productivity and reduced absenteeism
Competitive advantage in talent recruitment
Addresses root cause of many chronic conditions
The Case AGAINST Coverage
High upfront costs with uncertain long-term ROI
50% discontinuation rate within first year
Employee turnover may transfer benefits to next employer
Premium increases up to 14%
No generic alternatives for 5+ years
The Employee Turnover Problem
Average employee tenure is 2-3 years at many companies. If ROI requires 2+ years of continuous treatment, you may be funding benefits that materialize at a future employer. This is a real consideration for organizations with high turnover.
If You Cover: Utilization Management Framework
85% of employers offering GLP-1 coverage use utilization management to control costs. Here are the most common strategies.
BMI Eligibility Thresholds
Threshold | Description | Notes |
|---|---|---|
BMI ≥ 30 (Class I Obesity) | Standard threshold aligned with FDA approval. Broadest eligibility. | Most Common |
BMI ≥ 35 (Class II Obesity) | Limits coverage to higher-risk patients. Reduces utilization by approximately 40%. | Stricter |
BMI ≥ 27 with Comorbidity | Covers lower-BMI patients if they have hypertension, cardiovascular disease, high cholesterol, or sleep apnea. | |
BMI ≥ 40 (Class III Obesity) | Limits to highest-risk population. May face employee pushback. | Most Restrictive |
Prior Authorization Requirements
Requirement | Description | Adoption |
|---|---|---|
Prior Authorization | Require pre-approval before coverage. Standard practice. | 78% use this |
Re-Authorization with Progress Criteria | Require 5% weight loss within 6 months for continued coverage. | |
Step Therapy | Require trying lower-cost options first (metformin for diabetics, lifestyle programs for weight loss). | 63% use this |
Lifestyle Program Requirements
Requirement | Description | Adoption |
|---|---|---|
Diet/Exercise Program Participation | Must be enrolled in physician-supervised weight management program. | 69% require |
Nutritional Counseling | Require ongoing dietitian visits for continued coverage. | |
Health Coaching | Combine medication with behavioral support for better outcomes and adherence. |
Decision Framework: Should You Cover?
When to Cover vs. When to Wait
Your Situation | Lean Toward Covering | Lean Toward Waiting |
|---|---|---|
Workforce Demographics | Older workforce, high obesity rates | Young workforce, low chronic disease burden |
Employee Tenure | Long average tenure (5+ years) | High turnover (under 3 years average) |
Current Health Spend | High cardiac/diabetes claims | Low chronic disease costs |
Competitive Position | Tight labor market, recruiting challenges | Strong employer brand, low turnover |
Budget Flexibility | Can absorb 2-5% pharmacy increase | Already at or over healthcare budget |
Risk Tolerance | Willing to invest for long-term outcomes | Need predictable, near-term ROI |
If You’re Not Ready to Cover
There’s no shame in waiting. 57% of employers with 200+ employees don’t currently cover GLP-1s for weight loss. Here’s what to communicate:
Acknowledge employee interest — “We know these medications are generating a lot of attention.”
Explain your reasoning — “We’re monitoring the research on long-term outcomes and cost-effectiveness.”
Set a review timeline — “We’ll revisit this decision during our 2026 renewal.”
Offer alternatives — Enhance coverage for nutrition counseling, gym memberships, or weight management programs.
Watch for Market Changes
Several factors could change the calculus in 2026-2027:
Novo Nordisk now offers Wegovy direct-to-consumer at $499/month (down from $1,300+)
Compounded versions are available at lower cost (though with quality questions)
Oral GLP-1s in development could be cheaper and easier to take
Medicare may begin coverage, which could pressure commercial pricing
Your 2026 Planning Checklist
Questions to Answer Before Your Decision
What is our current obesity prevalence and related claims cost?
What is our average employee tenure? Will we see the ROI?
What are our PBM’s contracted rates and rebates for GLP-1s?
What utilization management requirements will we implement?
What BMI threshold makes sense for our population?
Will we require lifestyle program participation?
What is the projected impact on total pharmacy spend?
How will this affect our renewal rates and employee premiums?
What are our peer employers doing?
How will we communicate the decision to employees?
The Bottom Line
There’s no universally “right” answer on GLP-1 coverage. The decision depends on your workforce demographics, budget constraints, competitive position, and risk tolerance.
What we know for certain:
The drugs work — Weight loss is real, and cardiovascular benefits are emerging.
The costs are high — And will remain high until generics arrive (5+ years away).
Utilization management is essential — Unrestricted coverage is unsustainable for most employers.
The market is evolving — Pricing, formulations, and evidence will all change.
Make a deliberate decision based on your specific situation. Revisit it annually. And whatever you decide, communicate clearly with your employees.
Need Help Analyzing Your Options?
We help employers understand their healthcare spend and make data-driven benefits decisions. Let’s look at your claims data and model the impact of GLP-1 coverage for your specific population.
Sources
KFF. “Perspectives from employers on the costs and issues associated with covering GLP-1 agonists for weight loss.” https://www.healthsystemtracker.org/brief/perspectives-from-employers-on-the-costs-and-issues-associated-with-covering-glp-1-agonists-for-weight-loss/
SHRM. “Employer Coverage of GLP-1 Drugs Jumps.” https://www.shrm.org/topics-tools/news/benefits-compensation/employer-coverage-of-glp-1-drugs-jumps
Blue Cross Blue Shield. “GLP-1 Drugs Could Raise Employer Health Premiums.” https://www.bcbs.com/news-and-insights/article/glp-1-could-increase-employer-premiums
WTW. “GLP-1 update: Coverage trends and market developments.” https://www.wtwco.com/en-us/insights/2025/09/glp-1-update-coverage-trends-and-market-developments
CNBC. “GLP-1s can help employers lower medical costs in 2 years, new study finds.” https://www.cnbc.com/2025/04/30/glp-1s-employers-lower-medical-costs-study.html
Truveris. “How Pharmacy Plans Are Managing GLP-1 Coverage in 2025.” https://truveris.com/managing-glp-1-coverage/
Sequoia. “Covering GLP-1 Drugs: Employers’ Top Questions Answered.” https://www.sequoia.com/2025/11/employer-questions-about-glp-1/
Quantum Health. “Escalating specialty drug and GLP-1 costs—and the strategies to fight them.” https://quantum-health.com/blog/escalating-specialty-drug-and-glp-1-costs—and-the-strategies-to-fight-them/
Mercer. “GLP-1 considerations for 2026: Your questions answered.” https://www.mercer.com/en-us/insights/us-health-news/glp-1-considerations-for-2026-your-questions-answered/
EBRI. “GLP-1 Coverage and Its Impact on Employment-Based Health Plan Premiums.” https://www.ebri.org/content/full/glp-1-coverage-and-its-impact-on-employment-based-health-plan-premiums–a-simulation-based-analysis
MedicalBills.com Research Team